Invention Grant
- Patent Title: Small molecule antagonist compound TAC5 series having toll-like receptor 3/7/8/9 inhibitory function
-
Application No.: US17057967Application Date: 2019-05-20
-
Publication No.: US11629155B2Publication Date: 2023-04-18
- Inventor: Sangdon Choi , Eunha Kim
- Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
- Applicant Address: KR Suwon-si
- Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
- Current Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
- Current Assignee Address: KR Suwon-si
- Agency: Sughrue Mion, PLLC
- Priority: KR10-2018-0058503 20180523,KR10-2018-0107638 20180910
- International Application: PCT/KR2019/005978 WO 20190520
- International Announcement: WO2019/225920 WO 20191128
- Main IPC: C07D498/04
- IPC: C07D498/04 ; C07D213/72 ; C07D401/04

Abstract:
A small molecule antagonist compound having a toll-like receptor 3/7/8/9 inhibitory function and its use in inhibiting TLR7, TLR8, TLR9 and TLR3 are disclosed. A novel compound expressed by TAC5 and TAC5-a, TAC5-c, TAC5-d or TAC5-e which are derivatives thereof not only prevents TNFα secretion, NFkB activation, IkB degradation and MAPKs phosphorylation induced by poly(I:C) (TLR3 agonist), IMQ (TLR7 agonist), CL075 (TLR7/8 agonist), R848 (TLR7/8 agonist), TL8 (TLR8 agonist) or CpG ODN (TLR9 agonist), but also inhibits generation of inflammatory cytokine, and thus is highly advantageous for preventive or therapeutic use for TLR3/7/8/9-related autoimmune diseases and inflammatory diseases including systemic lupus erythematosus, psoriasis and the like.
Public/Granted literature
- US20210214372A1 SMALL MOLECULE ANTAGONIST COMPOUND TAC5 SERIES HAVING TOLL-LIKE RECEPTOR 3/7/8/9 INHIBITORY FUNCTION Public/Granted day:2021-07-15
Information query